You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ANTIIDIOTYPE MAB:AN ANTIANGIOGENIC /ANTIMETASTATIC AGENT

    SBC: PIVOTAL BIOSCIENCES            Topic: N/A

    Angiogenesis (new blood vessel formation) is a critical step for tumor growth and metastasis, and its inhibition is currently the most promising approach for cancer therapy. Contortrostatin (ON) is a protein isolated from southern copperhead snake venom, which has been shown to effectively block angiogenesis, as well as metastasis. The potent inhibitory effect of CN on cancer ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-inflammatory pathways, although other anti-inflammatory ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Anti Inflammatory Membranes for Implantable Biosensors

    SBC: APPLIED TISSUE AND MATERIALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The prolonged inflammatory response to an implant is one of the primary causes for the failure to integrate implanted devices into tissue. The source of inflammation common to almost all implants is the foreign body response. Based on evidence in the literature and from our research team, the inflammatory response is mediated by the reactive oxygen species gene ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Targeted Pb-212 therapy in preclinical animal tests has shown a cure in groups receiving the highest dose of this therapy. Scaling the dose that was most efficacious in animal studies to people would bring the human dose required from 50 to 100 mCi. This application will research an approach that would provide a generator system that would support these require ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. A Percutaneous Ultrasound-Guided Catheter for Organ and Vascular Access

    SBC: INNOSCION, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular disease and cancer. An interventional catheter with ultrasound imaging capability will be developedto enable image-guided access to blood vessels and internal organs. Computer simulations and preliminary data using a transducer similar to that ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. A Percutaneous Ultrasound-Guided Catheter for Organ and Vascular Access

    SBC: PERCEPTIVE NAVIGATION LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular disease and cancer An interventional catheter with forward viewing ultrasound imaging capability will be developed to enable image guided access to blood vessels and internal organs Phase experiments demonstrate feasibility of building a hi ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: SCRIBE BIOSCIENCES, INC.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government